+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID06881784

Phase 3 Randomized Study Comparing Daraxonrasib and Docetaxel in Patients With Previously Treated RAS Mutated Non-Small Cell Lung Cancer

Led by Revolution Medicines, Inc. · Updated on 2026-09-29

590

Participants Needed

158

Research Sites

156 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of a new drug called daraxonrasib compared to the chemotherapy drug docetaxel in patients with non-small cell lung cancer NSCLC who have specific RAS gene mutations and have already received treatment. This global, randomized, open-label Phase 3 study aims to find out if daraxonrasib can improve how long patients live without their cancer worsening or overall survival compared to standard chemotherapy. Participants are randomly assigned to one of two groups one group receives daraxonrasib as oral tablets, and the other group receives docetaxel through intravenous infusion. The study follows patients over several years to compare the outcomes of these treatments. Patients receive treatment according to their assigned group and are monitored regularly throughout the study period. During the study, participants will have assessments including scans to measure tumor size, tests to check organ function, and questionnaires about quality of life. Researchers will evaluate progression-free survival and overall survival as main outcomes, along with the safety and tolerability of the treatments. The study lasts up to approximately four years, with ongoing monitoring of patients health and treatment responses.

CONDITIONS

Brief Title

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Research Team

R

Revolution Medicines Study Director

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here